title: Limited macular translocation for the management of subfoveal choroidal neovascularization after photodynamic therapy.
abstract: OBJECTIVE
  To report our initial experience of limited macular translocation in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration following photodynamic therapy with verteporfin.
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  Retrospective review of four eyes of four consecutive patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who underwent effective limited macular translocation following photodynamic therapy. The mean logarithm of minimal angle of resolution preoperative best-corrected visual acuity was 20/190 (range, 20/150 to 20/200), and in all eyes the visual acuity was 20/150 or worse. The major outcome measures were postoperative visual acuity and complications related to the surgery.
  
  
  RESULTS
  The mean postoperative follow-up was 6.75 months (range, 6-8 months). Postoperative best-corrected visual acuity improved by 2 or more Snellen lines of visual acuity in three of four eyes (75%) and remained within 1 line in one of four eyes (25%). The mean postoperative best-corrected visual acuity was 20/100 (range, 20/40 to 20/150), and in two of the four eyes (50%) the visual acuity achieved was 20/100 or better. No complication was observed.
  
  
  CONCLUSIONS
  Limited macular translocation may be a viable option in patients who have previously undergone photodynamic therapy.
authors.affiliation: Doheny Retina Institute at the Doheny Eye Center, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA.
authors.forename: Gildo Y
authors.initials: GY
authors.lastname: Fujii
authors.forename: Eugene
authors.initials: E
authors.lastname: de Juan
authors.forename: Mark S
authors.initials: MS
authors.lastname: Humayun
authors.forename: Tom S
authors.initials: TS
authors.lastname: Chang
mesh_terms: D000368:Aged; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008266:Macula Lutea / Q000637:transplantation*; D008268:Macular Degeneration / Q000150:complications; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012189:Retrospective Studies; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin